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Abstract
One hundred thirty-one assays were performed to determine the level of specific IgE to major molecular components of the birch
pollen—rBet v 1, timothy grass pollen—rPhl p1, rPhl p 5b, and house dust mites—nDer p1, rDer p2 as well as to the minor
components of birch pollen—rBet v 2, rBet v 4, timothy grass pollen—rPhl p7, rPhl p 12, and house dust mites rDer p10 in
patients with asthma (N = 66) and allergic rhinitis (N = 65). It is well established that sensitization to major and minor allergens
facilitates the selection of an allergen for the allergen-specific immunotherapy (ASIT). According to the concept of molecular-
based allergen diagnostics, the ASIT efficacy is expected to be high when IgЕ to major components are present and antibodies to
minor components are absent. When elevated IgЕ levels to major and minor ASIT proteins are present, a moderate ASITefficacy
is expected.
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1 Introduction
Molecular identification of allergen components involved in
the atopic and autoimmune diseases became possible with
the practical application of biotechnologies. Panels of recom-
binant and natural molecules for various allergens have been
developed (tree, grain and weed pollens, house dust mites,
food-borne allergens, and pet dander) and used for diagnos-
tic. Natural extracts used in a routine practice contain large
number of epitopes. Therefore, utilizing molecular compo-
nents of each allergen increases the sensitivity and specificity
of diagnostic tests. Molecular (component) diagnostics uti-
lized in the ImmunoCAP technology (Phadia, Sweden) has
been proven valuable to identify the allergen. Molecular-
based allergy (MA) diagnostics is an approach used to map
the allergen sensitization of a patient at a molecular level,
using purified natural or recombinant allergenic molecules
(allergen components) instead of allergen extracts (A WAO-
ARIA-GA2LEN consensus document on molecular-based al-
lergy diagnostics) [1, 2]. The most important aspects of MA
diagnostics are ability to identify a causative molecule, dis-
criminate specific and cross-reactive molecules and capabil-
ity to determine the structure of the allergen [3].
One of the most important aspects of MA is the eval-
uation of the effectiveness of allergen-specific immuno-
therapy (ASIT) in patients with seasonal and allergic
rhinoconjunctivitis, atopic bronchial asthma, and anaphy-
lactic reactions [4–6]. MA of the sensitization profiles
improves the selection of patients for the ASIT and min-
imizes the use of ASIT in patients with polysensitization
(sensitization to three or more groups of allergens) [6–8].
Recent study has shown that the use of MA improved
the ASIT results when compared to prick tests [5].
Although the MA is currently used in clinical allergy
diagnosis, further studies are needed to select the catego-
ries of patients for ASIT.
The ImmunoCAP (Phadia) technology, which is used for
MA, is designed to detect ultra-low concentrations of immu-
noglobulins and inflammation markers in extremely small
sample size. Technically, this is achieved by using a solid
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